908 Devices’ (MASS) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a report published on Friday morning,Weiss Ratings reports.

Other equities analysts have also recently issued reports about the stock. Stephens reissued an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Leerink Partners restated a “market perform” rating and set a $4.00 price objective (down from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Leerink Partnrs lowered shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Finally, Stifel Nicolaus dropped their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, 908 Devices currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Down 8.3 %

Shares of NASDAQ MASS opened at $2.76 on Friday. The company’s fifty day moving average is $2.52 and its 200-day moving average is $2.91. The stock has a market cap of $96.11 million, a price-to-earnings ratio of -1.56 and a beta of 0.99. 908 Devices has a twelve month low of $1.81 and a twelve month high of $7.56.

Institutional Investors Weigh In On 908 Devices

A number of hedge funds and other institutional investors have recently made changes to their positions in MASS. Two Sigma Advisers LP acquired a new stake in shares of 908 Devices during the fourth quarter worth $30,000. Prudential Financial Inc. acquired a new stake in 908 Devices in the 4th quarter valued at $34,000. Occudo Quantitative Strategies LP acquired a new stake in 908 Devices in the 4th quarter valued at $36,000. Two Sigma Investments LP acquired a new stake in 908 Devices in the 4th quarter valued at $42,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in 908 Devices in the 3rd quarter valued at $45,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.